Safety and Efficacy of 8-mg Once-daily vs 4-mg Twice-daily Silodosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (SILVER Study): A 12-Week, Double-blind, Randomized, Parallel, Multicenter Study
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Silodosin for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular TolerabilityPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
- Conversion to Silodosin in Men on Conventional α1-Blockers for Symptomatic Benign Prostatic HyperplasiaLUTS: Lower Urinary Tract Symptoms, 2010
- Pharmacokinetic Profile of Silodosin in Clinical PracticeYAKUGAKU ZASSHI, 2006
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinicianBJU International, 2004
- Tamsulosin: an overviewWorld Journal of Urology, 2002
- Effect of KMD‐3213, an α1A‐adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogsInternational Journal of Urology, 2001
- Introduction and Concluding RemarksEuropean Urology, 1999
- Effect of KMD-3213, an α1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aortaEuropean Journal of Pharmacology, 1996
- Pharmacological evidence of distinct oci‐adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral arteryBritish Journal of Pharmacology, 1994
- A three month double‐blind study of doxazosin as treatment for benign prostatic bladder outlet obstructionBritish Journal of Urology, 1994